Irinotecan and Ifosfamide Combination is an Effective and Safe Option in Patients with Refractory Small Cell Lung Cancer: A Retrospective Cross-Sectional Study

KARAAĞAÇ M., ARTAÇ M., SEZGİN GÖKSU S., Eryilmaz M. K., COŞKUN H. Ş., Bozcuk H.

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, vol.4, no.2, pp.172-176, 2020 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 4 Issue: 2
  • Publication Date: 2020
  • Doi Number: 10.14744/ejmo.2020.15578
  • Journal Name: EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.172-176
  • Keywords: Chemotherapy, ifosfamide, irinotecan, small cell lung cancer, survival, PHASE-II TRIAL, COMPARING CISPLATIN, ETOPOSIDE, CHEMOTHERAPY, CARBOPLATIN, TOPOTECAN, 2ND-LINE, EFFICACY
  • Akdeniz University Affiliated: Yes

Abstract

Objectives: Recurrent and progressive small cell lung cancer (SCLC) has a very poor prognosis, and treatment options are limited. Combination of irinotecan with ifosfamide ( I-I regimen) in SCLC has limited preliminary data. In this study, we aimed to evaluate the efficacy and toxicity of I-I regimen in patients with previously treated SCLC.